Betulinic acid as a potent and complex antitumor phytochemical: A minireview

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 7, 2014, Pages 936-945

  Gheorgheosu, Dorina ^a   Duicu, Oana ^a   Dehelean, Cristina ^a   Şoica, Codruţa ^a   Muntean, Danina ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiogenesis; Anti tumor; Betulinic acid; Melanoma; Mitochondria

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETULIC ACID; PLANT MEDICINAL PRODUCT; TRITERPENE;

ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; HUMAN; METASTASIS; NEOPLASMS; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PHYTOCHEMICALS; TRITERPENES;

EID: 84905667731     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140223192148     Document Type: Article

References (85)

1. Gheorgheosu, D.; Jung, M.; Ören, B.; Schmid, T.; Dehelean, C.; Muntean, D.; Brüne, B. Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol. Chem., 2013, 394(6), 773-781.
2. Pisha, E.; Chai, H.; Lee, I.S.; Chagwedera, T.E.; Farnsworth, N.R.; Cordell, G.A.; Beecher, C.W.; Fong, H.H.; Kinghorn, A.D.; Brown, D.M.; Mansukh, C.W.; Monroe, E.W.; Tina, J.; Hieken, T. K.; Das, G.; John, M. P. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med., 1995, 1(10), 1046-1051.
3. Fulda, S.; Friesen, C.; Los, M.; Scaffidi, C.; Mier, W.; Benedict, M.; Nuñez, G.; Krammer, P.H.; Peter, M.E.; Debatin, K.M. Betulinic acid triggers CD95 (APO-1/Fas) and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 1997, 57(21), 4956-4964.
4. Fulda, S.; Scaffidi, C.; Susin, S.A.; Krammer, P.H.; Kroemer, G.; Peter, M.E.; Debatin, K.M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem., 1998, 273(51), 33942-33948.
5. Schmidt, M.L.; Kuzmanoff, K.L.; Ling-Indeck, L.; Pezzuto, J.M. Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur. J. Cancer, 1997, 33(12), 2007-2010.
6. Zuco, V.; Supino, R.; Righetti, S.C.; Cleris, L.; Marchesi, E.; Gambacorti-Passerini, C.; Formelli, F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett., 2002, 175(1), 17-25.
7. Kashiwada, Y.; Hashimoto, F.; Cosentino, L.M.; Chen, C.H.; Garrett, P.E.; Lee, K.H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J. Med. Chem., 1996, 39(5), 1016-1017.
8. Steele, J.C.; Warhurst, D.C.; Kirby, G.C.; Simmonds, M.S. In vitro and in vivo evaluation of betulinic acid as an antimalarial. Phytother. Res., 1999, 13(2), 115-119.
9. Zdzisińska, B.; Rzeski, W.; Paduch, R.; Szuster-Ciesielska, A.; Kaczor, J.; Wejksza, K.; Kandefer-Szerszeń, M. Differential effect of betulin and betulinic acid on cytokine production in human whole blood cell cultures. Pol. J. Pharmacol., 2003, 55(2), 235-238.
10. Takada, Y.; Aggarwal, B. B. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: Abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J. Immunol., 2003, 171(6), 3278-3286.
11. Viji, V.; Helen, A.; Luxmi, V.R. Betulinic acid inhibits endotoxin-stimulated phosphorylation cascade and pro-inflammatory prostaglandin E(2) production in human peripheral blood mononuclear cells. Br. J. Pharmacol., 2011, 162(6), 1291-1303.
12. Ren, W.; Qin, L.; Xu, Y.; Cheng, N. Inhibition of betulinic acid to growth and angiogenesis of human colorectal cancer cell in nude mice. Chinese-German J. Clin. Oncol., 2010, 9, 153-157.
13. Dehelean, C.A.; Feflea, S.; Ganta, S.; Amiji, M. Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J. Biomed. Nanotechnol., 2011, 7(2), 317-324.
14. Shin, J.; Lee, H.J.; Jung, D.B.; Jung, J.H.; Lee, H.J.; Lee, E.O.; Lee, S.G.; Shim, B.S.; Choi, S.H.; Ko, S.G.; Ahn, K.S.; Jeong, S.J.; Kim, S.H. Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One, 2011, 6(6), e21492.
15. Gao, Y.; Jia, Z.; Kong, X.; Li, Q.; Chang, D. Z.; Wei, D.; Le, X.; Suyun, H.; Huang, S.; Wang, L.; Xie, K. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res., 2011, 71(15), 5182-5193.
16. Yun, Y.; Han, S.; Park, E.; Yim, D.; Lee, S.; Lee, C.K.; Cho, K.; Kim, K. Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages. Arch. Pharm. Res., 2003, 26(12), 1087-1095.
17. Shikov, A.N.; Djachuk, G.I.; Sergeev, D.V.; Pozharitskaya, O.N.; Esaulenko, E.V.; Kosman, V.M.; Makarov, V.G. Birch bark extract as therapy for chronic hepatitis C--a pilot study. Phytomedicine, 2011, 18(10), 807-810.
18. Zheng, Z.W.; Song, S.Z.; Wu, Y.L.; Lian, L.H.; Wan, Y.; Nan, J.X. Betulinic acid prevention of d-galactosamine/lipopolysaccharide liver toxicity is triggered by activation of Bcl-2 and antioxidant mechanisms. J. Pharm. Pharmacol., 2011, 63(4), 572-578.
19. Wan, Y.; Wu, Y.L.; Lian, L.H.; Xie, W.X.; Li, X.; Ouyang, B.Q.; Bai, T.; Li, Q.; Yang, N.; Nan, J.X. The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-κB nuclear protein translocation. Chem. Biol. Interact., 2012, 195(3), 215-223.
20. Lu, Q.; Xia, N.; Xu, H.; Guo, L.; Wenzel, P.; Daiber, A.; Münzel, T.; Förstermann, U.; Li, H. Betulinic acid protects against cerebral ischemia-reperfusion injury in mice by reducing oxidative and nitrosative stress. Nitric Oxide, 2011, 24(3), 132-138.
21. Wick, W.; Grimmel, C.; Wagenknecht, B.; Dichgans, J.; Weller, M. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther., 1999, 289(3), 1306-1312.
22. Ganguly, A.; Das, B.; Roy, A.; Sen, N.; Dasgupta, S.B.; Mukhopadhayay, S.; Majumder, H.K. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res., 2007, 67(24), 11848-11858.
23. Melzig, M.F.; Bormann, H. Betulinic acid inhibits aminopeptidase N activity. Planta Med., 1998, 64(7), 655-657.
24. Tan, Y.; Yu, R.; Pezzuto, J.M. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin. Cancer Res., 2003, 9(7), 2866-2875.
25. Patocka, J. Biologically active pentacyclic triterpenes and their current medicine signification. J. Appl. Biomed., 2003, 1, 7-12.
26. Bruckner, G.; Kovacs, J.; Koczka, I. Occurrence of betulinic acid in the bark of the plane tree. J. Chem. Soc., 1948, 948-951.
27. Yogeeswari, P.; Sriram, D. Betulinic acid and its derivatives: A review on their biological properties. Curr. Med. Chem., 2005, 12(6), 657-666.
28. Dehelean, C.A.; Cinta Pinzaru, S.; Peev, C.I.; Soica, C.; Antal D.S. Characterisation of birch tree leaves, buds and bark dry extracts with antitumor activity. J. Optoelectron. Adv. M., 2007, 9(3), 783-787.
29. Şoica, C.; Peev, C.; Dehelean, C.; Aluas, M.; Zupko, I.; Kasa, P. and Alexa, E. Physico-chemical comparison study of betulinic acid, betulin and birch bark extract and in vitro investigation of their cytotoxic effects towards skin epidermoid carcinoma (A431), breast carcinoma (MCF7) and cervix adenocarcinoma (HeLa) celllines, Nat. Prod. Res., 2012, 26(10), 968-974.
30. Dehelean, C.A.; Şoica, C.; Ledeţi, I.; Aluaş, M.; Zupko, I.; Gluşcan, A.; Cinta-Pinzaru, S.; Munteanu, M. Study of the betulin enriched birch bark extracts effects on human carcinoma cells and ear inflammation. Chem. Cent. J., 2012, 6 (1), 6-137.
31. Fulda, S.; Jeremias, I.; Steiner, H.H.; Pietsch, T.; Debatin, K.M. Betulinic acid: A new cytotoxic agent against malignant braintumor cells. Int. J. Cancer, 1999, 82(3), 435-441.
32. Selzer, E.; Pimentel, E.; Wacheck, V.; Schlegel, W.; Pehamberger, H.; Jansen, B.; Kodym, R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest. Dermatol., 2000, 114(5), 935-940.
33. Liu, W.K.; Ho, J.C.; Cheung, F.W.; Liu, B.P.; Ye, W.C.; Che, C.T. Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line. Eur. J. Pharmacol., 2004, 498(1-3), 71-78.
34. Hata, K.; Hori, K.; Takahashi, S. Differentiationand apoptosis-inducing activities by pentacyclic triterpenes on a mouse melanoma cell line. J. Nat. Prod., 2002, 65(5), 645-648.
35. Ciurlea, S.; Dehelean, C.A.; Ionescu, D.; Berko, S.; Csanyi, E.; Hadaruga, D.I.; Ganta, S.; Amiji, M. A comparative study regarding melanoma activity of Betulinic acid on topical ointment vs. systemic nanoemulsion delivery systems. J. Agroalimentary Proc. Technol., 2010, 16(4), 420-426.
36. Kessler, J.H.; Mullauer, F.B.; De Roo, G.M.; Medema, J.P. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett., 2007, 251, 132-145.
37. Ehrhardt, H.; Fulda, S.; Führer, M.; Debatin, K.M.; Jeremias, I. Betulinic acid-induced apoptosis in leukemia cells. Leukemia, 2004, 18(8), 1406-1412.
38. Thurnher, D.; Turhani, D.; Pelzmann, M.; Wannemacher, B.; Knerer, B.; Formanek, M.; Wacheck, V.; Selzer, E. Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells. Head Neck, 2003, 25(9), 732-740.
39. Rzeski, W.; Stepulak, A.; Szymański, M.; Sifringer, M.; Kaczor, J.; Wejksza, K.; Zdzisińska, B.; Kandefer-Szerszeń, M. Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn. Schmiedebergs Arch. Pharmacol., 2006, 374(1), 11-20.
40. Yang, L.J.; Chen, Y.; Ma, Q.; Fang, J.; He, J.; Cheng, Y.Q.; Wu, Q.L. Effect of betulinic acid on the regulation of Hiwi and cyclin B1 in human gastric adenocarcinoma AGS cells. Acta Pharmacol. Sin., 2010, 31(1), 66-72.
41. Wu, Q.; He, J.; Fang, J.; Hong, M. Antitumor effect of betulinic acid on human acute leukemia K562 cells in vitro. J. Huazhong Univ. Sci. Technol. Med. Sci., 2010, 30(4), 453-457.
42. Jung, G.R.; Kim, K.J.; Choi, C.H.; Lee, T.B.; Han, S.I.; Han, H.K.; Lim, S.C. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin. Pharmacol. Toxicol., 2007, 101(4), 277-285.
43. Surowiak, P.; Drag, M.; Materna, V.; Dietel, M.; Lage, H. Betulinic acid exhibits stronger cytotoxic activity on the normal melanocyte NHEM-neo cell line than on drug-resistant and drug-sensitive MeWo melanoma cell lines. Mol. Med. Rep., 2009, 2(4), 543-548.
44. Dehelean, C.A.; Soica, C.; Peev, C.; Ciurlea, S.; Feflea, S.; Kasa P A Pharmaco-toxicological evaluation of betulinic acid mixed with hydroxipropil gamma cyclodextrin on in vitro and in vivo models. Farmacia, 2011, 59(1), 51-59.
45. Fulda, S.; Jeremias, I.; Debatin, K.M. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene, 2004, 23(46), 7611-7620.
46. Fulda, S.; Debatin, K.M. Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia, 2005, 7(2), 162-170.
47. Cichewicz, R.H.; Kouzi, S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev., 2004, 24(1), 90-114.
48. Wachsberger, P.R.; Burd, R.; Wahl, M.L.; Leeper, D.B. Betulinic acid sensitization of low pH adapted human melanoma cells to hyperthermia. Int. J. Hyperthermia, 2002, 18(2), 153-164.
49. Raghuvar Gopal, D.V.; Narkar, A.A.; Badrinath, Y.; Mishra, K.P.; Joshi, D.S. Betulinic acid induces apoptosis in human chronic myelogenous leukemia (CML) cell line K-562 without altering the levels of Bcr-Abl. Toxicol. Lett., 2005, 155(3), 343-351.
50. Chintharlapalli, S.; Papineni, S.; Ramaiah, S.K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res., 2007, 67(6), 2816-2823.
51. Udeani, G.O.; Zhao, G.M.; Geun Shin, Y.; Cooke, B.P.; Graham, J.; Beecher, C.W.; Kinghorn, A.D.; Pezzuto, J.M. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm. Drug Dispos., 1999, 20(8), 379-383.
52. Mertens-Talcott, S.U.; Noratto, G.D.; Li, X.; Angel-Morales, G.; Bertoldi, M.C.; Safe, S. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol. Carcinog., 2013, 52(8), 591-602.
53. Hsu, T.I.; Wang, M.C.; Chen, S.Y.; Huang, S.T.; Yeh, Y.M.; Su, W.C.; Chang, W.C.; Hung, J.J. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth. Mol. Pharmacol., 2012, 82(6), 1115-1128.
54. Dehelean, C.A.; Feflea, S.; Gheorgheosu, D.; Ganta, S.; Cimpean, A.M.; Muntean, D.; Amiji, M.M. Anti-angiogenic and anti-cancer evaluation of betulin nanoemulsion in chicken chorioallantoic membrane and skin carcinoma in Balb/c mice. J. Biomed. Nanotechnol., 2013, 9(4), 577-589.
55. Fulda, S. Betulinic acid: A natural product with anticancer activity. Mol. Nutr. Food Res., 2009, 53(1), 140-146.
56. Ciurlea, S.; Tiulea, C.; Csanyi, E.; Berko, S.; Toma, C.C.; Dehelean, C.A.; Loghin, F. A pharmacotoxicological evaluation of a betulin topical formulation tested on C57BL/6J mouse experimental nevi and skin lesions. Studia Univ. VG, SSV., 2010, 20(4), 5-9.
57. Huyke, C.; Laszczyk, M.; Scheffler, A.; Ernst, R.; Schempp, C.M. Treatment of actinic keratoses with birch bark extract: A pilot study. J. Dtsch. Dermatol. Ges., 2006, 4(2), 132-136.
58. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev., 2007, 87(1), 99-163.
59. Fulda, S. Betulinic Acid for cancer treatment and prevention. Int. J. Mol. Sci., 2008, 9(6), 1096-1107.
60. Fulda, S.; Kroemer, G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov. Today., 2009, 14(17-18), 885-890.
61. Mullauer, F.B.; Kessler, J.H.; Medema, J.P. Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion. Apoptosis, 2009, 14(2), 191-202.
62. Prasad, S.; Ravindran, J.; Aggarwal, B.B. NF-kappaB and cancer: How intimate is this relationship. Mol. Cell Biochem., 2010, 336(1-2), 25-37.
63. Madonna, G.; Ullman, C.D.; Gentilcore, G.; Palmieri, G.; Ascierto, P.A. NF-κB as potential target in the treatment of melanoma. J. Transl. Med., 2012, 10, 53, 1-53.
64. Kasperczyk, H.; La Ferla-Brühl, K.; Westhoff, M.A.; Behrend, L.; Zwacka, R.M.; Debatin, K.M.; Fulda, S. Betulinic acid as new activator of NF-kappaB: Molecular mechanisms and implications for cancer therapy. Oncogene, 2005, 24(46), 6945-6956.
65. Safe, S.H.; Prather, P.L.; Brents, L.K.; Chadalapaka, G.; Jutooru, I. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med. Chem., 2012, 12(10), 1211-1220.
66. Kaczynski, J.; Cook, T.; Urrutia, R. Sp1-and Krüppel-like transcription factors. Genome Biol., 2003, 4(2), 206.
67. Papineni, S.; Chintharlapalli, S.; Abdelrahim, M.; Lee, S.O.; Burghardt, R.; Abudayyeh, A.; Baker, C.; Herrera, L.; Safe, S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis, 2009, 30(7), 1193-1201.
68. Chadalapaka, G.; Jutooru, I.; Burghardt, R.; Safe, S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol. Cancer Res., 2010, 8(5), 739-50.
69. Chintharlapalli, S.; Papineni, S.; Lee, S.O.; Lei, P.; Jin, U.H.; Sherman, S.I.; Santarpia, L.; Safe, S. Inhibition of pituitary tumortransforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol. Carcinog., 2011, 50(9), 655-667.
70. Liu, X.; Jutooru, I.; Lei, P.; Kim, K.; Lee, S.O.; Brents, L.K.; Prather, P.L.; Safe, S. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a: ZBTB10 in breast cancer. Mol. Cancer Ther., 2012, 11(7), 1421-1431.
71. Higgins, K.J.; Abdelrahim, M.; Liu, S.; Yoon, K.; Safe, S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by p proteins. Biochem. Biophys. Res. Commun., 2006, 345(1), 292-301.
72. Abdelrahim, M.; Baker, C.H.; Abbruzzese, J.L.; Sheikh-Hamad, D.; Liu, S.; Cho, S.D.; Yoon, K.; Safe, S. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res., 2007, 67(7), 3286-3294.
73. Jutooru, I.; Chadalapaka, G.; Lei, P.; Safe, S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J. Biol. Chem., 2010, 285(33), 25332-25344.
74. Chadalapaka, G.; Jutooru, I.; Sreevalsan, S.; Pathi, S.; Kim, K.; Chen, C.; Crose, L.; Linardic, C.; Safe, S. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. Int. J. Cancer, 2013, 132(4), 795-806.
75. Folkman, J.; Shing, Y. Angiogenesis. J. Biol. Chem., 1992, 267(16), 10931-10934.
76. McMahon, G. VEGF receptor signaling in tumor angiogenesis. Oncologist, 2000, 5(1), 3-10.
77. Kwon, H.J.; Shim, J.S.; Kim, J.H.; Cho, H.Y.; Yum, Y.N.; Kim, S.H.; Yu, J. Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn. J. Cancer Res., 2002, 93(4), 417-425.
78. Mukherjee, R.; Jaggi, M.; Rajendran, P.; Siddiqui, M.J.; Srivastava, S.K.; Vardhan, A.; Burman, A.C. Betulinic acid and its derivatives as anti-angiogenic agents. Bioorg. Med. Chem. Lett., 2004, 14(9), 2181-2184.
79. Chintharlapalli, S.; Papineni, S.; Lei, P.; Pathi, S.; Safe, S. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 2011, 11, 371.
80. Karna, E.; Szoka, L.; Palka, J.A. Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol. Cell Biochem., 2010, 340(1-2), 15-20.
81. Shih, J.Y.; Yuan, A.; Chen, J.J.W.; Yang, P.C. Tumor-associated macrophage: Its role in cancer invasion and metastasis. J. Cancer Mol., 2006, 2(3), 101-106.
82. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest., 2009, 119, 1420-1428.
83. Zeisberg, M.; Neilson, E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest., 2009, 119, 1429-1437.
84. Manez, S.; Recio, M.C.; Giner, R.M.; Ríos, J.L. Effect of selected triterpenoids on chronic dermal inflammation. Eur. J. Pharmacol., 1997, 334(1), 103-105.
85. Yi, J.E.; Obminska-Mrukowicz, B.; Yuan, L.Y.; Yuan, H. Immunomodulatory effects of betulinic acid from the bark of white birch on mice. J. Vet. Sci., 2010, 11(4), 305-313.